Lilly ' s Neutralizing Antibody Bamlanivimab (LY-CoV555) Receives Interim Authorization from Health Canada as a Treatment for COVID-19

INDIANAPOLIS, Nov. 20, 2020 /PRNewswire/ -- Health Canada today granted authorization under the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 for the use of bamlanivimab...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials